奈达铂联合长春瑞滨结合同步放疗治疗晚期鼻咽癌的疗效分析  

Clinical observation of Nedaplatin and Vinorelbine chemotherapy combined with radiotherapy in the treatment of advanced Nasopharyngeal Carcinoma

作　　者：潘险峰[1] 唐曦[1] 徐炎华[1] 

机构地区：[1]华中科技大学附属荆州医院肿瘤科,湖北荆州433020

出　　处：《现代生物医学进展》2009年第21期4086-4087,4085,共3页Progress in Modern Biomedicine

摘　　要：目的:研究奈达铂联合长春瑞滨结合同步放射治疗晚期鼻咽癌的有效性和安全性。方法:选择我院收治41例病理证实为晚期鼻咽癌患者,给予奈达铂(100mg/m2,d1)和长春瑞滨(25mg/m2,d1,8)化疗,每21天为一周期,完成第一周期后行放疗,放疗期间同步化疗。结果:本组患者CR为70.7%,PR为26.8%,SD为2.4%,总有效率为97.6%,1a无复发生存率为97.6%,1a无远处转移生存率为87.8%,毒副反应主要为血液性毒性,治疗后均恢复,均可以耐受。结论:奈达铂联合长春瑞滨结合同步放射治疗晚期鼻咽癌近期疗效较好,耐受性良好且安全性较高。Objective：To observe the efficacy and security of neoadjuvant chemotherapy regimens with Nedaplatin and Vinorelbine plus radiotherapy in patients with advanced nasopharyngeal carcinoma. Methods：Forty-one patients with pathologically confirmed advanced nasopharyngeal carcinoma were treated by chemoradiotherapy after neoadjuvant chemotherapy with Nedaplatin（100mg/m2,d1） and Vinorelbine（25mg/m2,d1,8） from July 2004 to December 2007. Results：The overall response rates were 97.6%,including twenty-nine（70.7%） patients with complete responses,eleven（26.8%） patients with partial responses and one（2.4%） patients with stable disease. One years recurrence-free survival rates（RFS） and distant metastasis free survival rates（DMF） were 97.6% and 87.8%,respectively. The major adverse effect was hematological toxicity,mainly from grade I to grade III,which was regained through treatment. Conclusions：Neoadjuvant chemotherapy regimens with Nedaplatin and Vinorelbine plus radiotherapy is effective,good tolerance and safety in the treatment of advanced nasopharyngeal carcinoma.

关 键 词：奈达铂 长春瑞滨 化学治疗 放射治疗 

分 类 号：R739.63[医药卫生—肿瘤]